Methods of treating pain using neurotrophic factors
View Patent ↗The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
1. A method of treating neuropathic pain in a mammal, comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising (a) a polypeptide consisting of an amino acid sequence selected from the group consisting of amino acids 37-140 of SEQ ID NO:9 (NBN 104), amino acids 39-140 of SEQ ID NO:9 (NBN 102), and amino acids 42-140 of SEQ ID NO:9 (NBN 99), and (b) a pharmaceutically acceptable carrier.
2. The method of claim 1 , wherein the polypeptide consists of amino acids 37-140 of SEQ ID NO:9 (NBN 104).
3. The method of claim 1 , wherein the polypeptide consists of amino acids 39-140 of SEQ ID NO:9 (NBN 102).
4. The method of claim 1 , wherein the polypeptide consists of amino acids 42-140 of SEQ ID NO:9 (NBN 99).
5. A method of treating a peripheral neuropathy in a mammal, comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising (a) a polypeptide consisting of an amino acid sequence selected from the group consisting of amino acids 37-140 of SEQ ID NO:9 (NBN 104), amino acids 39-140 of SEQ ID NO:9 (NBN 102), and amino acids 42-140 of SEQ ID NO:9 (NBN 99), and (b) a pharmaceutically acceptable carrier.
6. The method of claim 5 , wherein the polypeptide consists of amino acids 37-140 of SEQ ID NO:9 (NBN 104).
7. The method of claim 5 , wherein the polypeptide consists of amino acids 39-140 of SEQ ID NO:9 (NBN 102).
8. The method of claim 5 , wherein the polypeptide consists of amino acids 42-140 of SEQ ID NO:9 (NBN 99).
9. The method of claim 6 , wherein the peripheral neuropathy is diabetic peripheral neuropathy.
10. The method of claim 7 , wherein the peripheral neuropathy is diabetic peripheral neuropathy.
11. The method of claim 8 , wherein the peripheral neuropathy is diabetic peripheral neuropathy.
12. The method of claim 2 , wherein the pharmaceutical composition is administered systemically.
13. The method of claim 3 , wherein the pharmaceutical composition is administered systemically.
14. The method of claim 4 , wherein the pharmaceutical composition is administered systemically.
15. The method of claim 6 , wherein the pharmaceutical composition is administered systemically.
16. The method of claim 7 , wherein the pharmaceutical composition is administered systemically.
17. The method of claim 8 , wherein the pharmaceutical composition is administered systemically.
18. The method of claim 9 , wherein the pharmaceutical composition is administered systemically.
19. The method of claim 10 , wherein the pharmaceutical composition is administered systemically.
20. The method of claim 11 , wherein the pharmaceutical composition is administered systemically.
21. The method of claim 12 , wherein the mammal is a human.
22. The method of claim 13 , wherein the mammal is a human.
23. The method of claim 14 , wherein the mammal is a human.
24. The method of claim 15 , wherein the mammal is a human.
25. The method of claim 16 , wherein the mammal is a human.
26. The method of claim 17 , wherein the mammal is a human.
27. The method of claim 18 , wherein the mammal is a human.
28. The method of claim 19 , wherein the mammal is a human.
29. The method of claim 20 , wherein the mammal is a human.